Journal of Lipid Research, Vol 34, 719-728, Copyright © 1993 by Lipid Research, Inc.

ARTICLES

Immunological properties of apoB-containing lipoprotein particles in human atherosclerotic arteries

A Tailleux, G Torpier, B Caron, JC Fruchart and C Fievet
SERLIA et INSERM U325, Institut Pasteur, Lille, France.

In this study, we have documented immunochemical properties of apolipoprotein (apo) B-containing particles (LpB) extracted from human atherosclerotic lesions obtained during vascular reconstructive surgery of patients. These properties were compared to those of particles purified from corresponding atherosclerotic plasma and healthy control plasma. LpB immunoreactivities were tested in solid phase competitive binding radioimmunoassays using five anti-apoB monoclonal antibodies (MAb) for which epitopes have been previously located on the protein. The regions encompassed amino acids 405 to 539 (MAb B1), 1854 to 1879 (MAb B4), 3506 (MAb BA11), and 4355 (MAb BL3). The fifth antibody (MAb BL5) recognizes a conformationally expressed epitope. LpB from lesions presented a significantly decreased immunoreactivity as compared to LpB from respective plasma except for the epitope recognized by MAb BA11 located precisely in the low density lipoprotein (LDL) receptor binding site. The accessibility of the four sequential epitopes was similar on LpB from atherosclerotic and healthy plasma while it was decreased for the conformational one in LpB from atherosclerotic samples. These altered immunoreactivities were not related to changes in chemical composition of LpB as this was quite comparable in all preparations. With regard to electronegativity, apoB fragmentation, immunological accessibility, and size distribution of the particles, changes seem to increase in the following order from healthy plasma, atherosclerotic plasma, and the corresponding lesions. The results confirm some structural characteristics of oxidatively modified particles from human atherosclerotic lesions and to a lesser degree from respective plasma, but more specifically demonstrate a global conformational change in LpB from lesions, this change being perhaps initiated in the plasma.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. Oorni and P. T. Kovanen PLA2-V: A Real Player in Atherogenesis Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 445 - 447. [Full Text] [PDF]

				K. Oorni, M. Sneck, D. Bromme, M. O. Pentikainen, K. A. Lindstedt, M. Mayranpaa, H. Aitio, and P. T. Kovanen Cysteine Protease Cathepsin F Is Expressed in Human Atherosclerotic Lesions, Is Secreted by Cultured Macrophages, and Modifies Low Density Lipoprotein Particles in Vitro J. Biol. Chem., August 13, 2004; 279(33): 34776 - 34784. [Abstract] [Full Text] [PDF]

				J. Zhang and H. Herscovitz Nascent Lipidated Apolipoprotein B Is Transported to the Golgi as an Incompletely Folded Intermediate as Probed by Its Association with Network of Endoplasmic Reticulum Molecular Chaperones, GRP94, ERp72, BiP, Calreticulin, and Cyclophilin B J. Biol. Chem., February 21, 2003; 278(9): 7459 - 7468. [Abstract] [Full Text] [PDF]

				E. Hurt-Camejo, G. Camejo, H. Peilot, K. Oorni, and P. Kovanen Phospholipase A2 in Vascular Disease Circ. Res., August 17, 2001; 89(4): 298 - 304. [Abstract] [Full Text] [PDF]

				M. O. Pentikäinen, M. T. Hyvönen, K. Öörni, T. Hevonoja, A. Korhonen, E. M. P. Lehtonen-Smeds, M. Ala-Korpela, and P. T. Kovanen Altered phospholipid-apoB-100 interactions and generation of extra membrane material in proteolysis-induced fusion of LDL particles J. Lipid Res., June 1, 2001; 42(6): 916 - 922. [Abstract] [Full Text]

				J. K. Hakala, K. Oorni, M. O. Pentikainen, E. Hurt-Camejo, and P. T. Kovanen Lipolysis of LDL by Human Secretory Phospholipase A2 Induces Particle Fusion and Enhances the Retention of LDL to Human Aortic Proteoglycans Arterioscler. Thromb. Vasc. Biol., June 1, 2001; 21(6): 1053 - 1058. [Abstract] [Full Text] [PDF]

				K. Öörni, M. O. Pentikäinen, M. Ala-Korpela, and P. T. Kovanen Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions J. Lipid Res., November 1, 2000; 41(11): 1703 - 1714. [Abstract] [Full Text]

				P. Sartipy, G. Camejo, L. Svensson, and E. Hurt-Camejo Phospholipase A2 Modification of Low Density Lipoproteins Forms Small High Density Particles with Increased Affinity for Proteoglycans and Glycosaminoglycans J. Biol. Chem., September 3, 1999; 274(36): 25913 - 25920. [Abstract] [Full Text] [PDF]

				U. Lundstam, E. Hurt-Camejo, G. Olsson, P. Sartipy, G. Camejo, and O. Wiklund Proteoglycans Contribution to Association of Lp(a) and LDL With Smooth Muscle Cell Extracellular Matrix Arterioscler. Thromb. Vasc. Biol., May 1, 1999; 19(5): 1162 - 1167. [Abstract] [Full Text] [PDF]

				J. K. Hakala, K. Oorni, M. Ala-Korpela, and P. T. Kovanen Lipolytic Modification of LDL by Phospholipase A2 Induces Particle Aggregation in the Absence and Fusion in the Presence of Heparin Arterioscler. Thromb. Vasc. Biol., May 1, 1999; 19(5): 1276 - 1283. [Abstract] [Full Text] [PDF]

				K. Oorni, J. K. Hakala, A. Annila, M. Ala-Korpela, and P. T. Kovanen Sphingomyelinase Induces Aggregation and Fusion, but Phospholipase A2 Only Aggregation, of Low Density Lipoprotein (LDL) Particles. TWO DISTINCT MECHANISMS LEADING TO INCREASED BINDING STRENGTH OF LDL TO HUMAN AORTIC PROTEOGLYCANS J. Biol. Chem., October 30, 1998; 273(44): 29127 - 29134. [Abstract] [Full Text] [PDF]

				M. Romano, E. Romano, S. Bjorkerud, and E. Hurt-Camejo Ultrastructural Localization of Secretory Type II Phospholipase A2 in Atherosclerotic and Nonatherosclerotic Regions of Human Arteries Arterioscler. Thromb. Vasc. Biol., April 1, 1998; 18(4): 519 - 525. [Abstract] [Full Text] [PDF]

				A.-M. Lefebvre, J. Peinado-Onsurbe, I. Leitersdorf, M. R. Briggs, J. R. Paterniti, J.-C. Fruchart, C. Fievet, J. Auwerx, and B. Staels Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1756 - 1764. [Abstract] [Full Text]

				E. Hurt-Camejo, U. Olsson, O. Wiklund, G. Bondjers, and G. Camejo Cellular Consequences of the Association of ApoB Lipoproteins With Proteoglycans: Potential Contribution to Atherogenesis Arterioscler. Thromb. Vasc. Biol., June 1, 1997; 17(6): 1011 - 1017. [Abstract] [Full Text]

				E. Hurt-Camejo, S. Andersen, R. Standal, B. Rosengren, P. Sartipy, E. Stadberg, and B. Johansen Localization of Nonpancreatic Secretory Phospholipase A2 in Normal and Atherosclerotic Arteries: Activity of the Isolated Enzyme on Low-Density Lipoproteins Arterioscler. Thromb. Vasc. Biol., February 1, 1997; 17(2): 300 - 309. [Abstract] [Full Text]

				P. Sartipy, B. Johansen, G. Camejo, B. Rosengren, G. Bondjers, and E. Hurt-Camejo Binding of Human Phospholipase A2 Type II to Proteoglycans. DIFFERENTIAL EFFECT OF GLYCOSAMINOGLYCANS ON ENZYME ACTIVITY J. Biol. Chem., October 18, 1996; 271(42): 26307 - 26314. [Abstract] [Full Text] [PDF]